Right now he is Bunt Single Al. . I have a feeling that he's is about to be thrown out attempting to steal second base.
Re: "In Fact, the total royalties for all of 2015 will be less than Pascoe's salary."
There you go again, Al. You attempt to pass your scare tactic statement as fact.
The fact that Sandoz expanded the marketing deal and continues to launch and gain approvals indicates that they are pleased with sales.
Re: "Are they waiting for the room temperature applicator like Canada is? If so, the later part of 2016 will be the soonest"
Al, you should know better than to make comments like this. There is nothing wrong with you taking a profit. Clearly you want back in at a lower price than $2.34, but misleading people about the Vitaros launches in Europe and Canada is just not right..
You should know that Sandoz, a Novartis company, has already launched the Cold Vitaros in Germany, Sweden and Belgium. Sandoz has also ordered product to support Vitaros Launches in Denmark, Finalnd, and Norway. Sandoz thought well enough of Cold Vitaros to achieve maketing approvals on their own in Norway, Finalnd, and Denmark. They also thought well enough of Vitaros to expand the marketing agreement to include some Asia Pacific nations.
You should know that Takeda has launched Cold Vitaros in the United Kingdom,
You should know that Cold Vitaros was shipped to Spain for launch by Recordati.
You should know that Laboratoires Majorelle received Cold Vitaros for their launch in France and they are only awaiting the reimbursement decision which should come very soon.
You should also know that Bracco has ordered Cold Vitaros for Italy.
No, Al, the European Marketing Partners are not waiting for Room Temp Vitaros, It looks like full speed ahead for Cold Vitaros in Europe.
I would not be surprised to see yet another Vitaros launch announcement in Europe this coming week.
In my opinion, the Vitaros launch in Canada was delayed only because of the sale of Abbott's Developed Markets Generics business to Mylan. That deal is expected to close soon. I believe that there is a good chance that Mylan does launch Cold Vitaros in Canada.
I am very pleased with Apricus' acquisition of U.S. Fispemifene rights, and I pretty sure that Alex Denner and Sarissa are too.
Warner Chilcott owned U.S. Vitaros rights and was moving forward with a small clinical studiy wihich the FDA requested. Avtavis bought Warner Chilcott and the study was cancelled.
According to Apricus Biosciences CEO Pascoe, the company is currently in talks with Actavis to move Vitaros forward in the USA. Apricus has developed a Room Temperature Dispenser for Vitaros.. Pascoe said that further clinical development of Vitaros in the USA would be Room Temperature version. Actavis does not hold rights to the Vitaros Room Temp Dispenser.
Actavis is talking to Actavis about reacquiring U.S. Vitaros rights. Another possibility is the two companies come to a licensing agreement regarding the Vitaros RTD.
The cold chain version of Vitaros has launched and continues to launch in Europe. I have heard of no problems with stability in Europe. Do you expect everyone to believe that the product is stable in Europe but not Canada?
Folks like you are here just to muddy the waters.
You should know that Abbott sold their Developed Markets Generics Business to Mylan. The deal is expected to close in the first quarter of 2015. Vitaros was part of the deal. I believe that Mylan will launch Vitaros in Canada.
It seems that Sandoz, a Novartis company, is doing very well with Vitaros in Europe. They have already launched in Germany, Sweden and Belgium. and are preparing to launch in Denmark, Norway and Finland.
Recordati has received product and should be launching in Spain anytime now. Laboratoires Majorelle will be launching Vitaros in France soon. Bracco has ordered product for their launch in Italy.
Sandoz and Apricus recently agreed to expand their marketing agreement to include some Asian Pacific nations. I doubt that Sandoz would do this if they were not having success with Vitaros.
Bic, your last "Feeling" was that APRI PPS would not exceed $2.05. When you get these "feelings" perhaps you should just do the opposite, WELCHER.
The Welcher was not too happy today. Maybe he should stop depending on foreign worms for info. Perhaps he would do much better with a good old domestic Red Wiggler.
Page 6 of today's Prospectus Supplement is very interesting.
"Board and Preemptive Rights; Resale Limitations
In connection with the purchase of the securities offered hereby pursuant to a subscription agreement, we have granted Sarissa Capital Management LP, or Sarissa, the right, but not the obligation, to appoint to our board of directors one individual, who shall be reasonably acceptable to the current members of our board. We have also granted Sarissa preemptive rights to participate in future equity issuances by us, subject to certain exceptions, so as to maintain its then-current percentage of beneficial ownership of our common stock. Sarissa will continue to have these board and preemptive rights until such time that it ceases to beneficially own at least fifty percent (50%) of the shares of our outstanding common stock that it
beneficially owned immediately after the completion of this offering (assuming, for this purpose, that the warrants issued in this offering were fully exercised), which we refer to as the Ownership Threshold. Until Sarissa (together with its controlled affiliates) ceases to satisfy the Ownership Threshold, we have also agreed not to sell any shares of common stock under the Common Stock Purchase Agreement, dated August 12, 2014, between Aspire Capital Fund, LLC and us without the prior written consent of Sarissa.
Under the subscription agreement with Sarissa, Sarissa has agreed not to resell the shares of common stock it purchases for a period of six months from the closing date of the offering..."
Looks like Sarissa is in for the long haul.
Court (says.simmon), It's not that simple. How many doctors would be willing to write an off label presciption of RayVa for ED? Also, if memory serves me correctly, RaVa and Vitaros have the same ingredients but not ithe same ratios.
Apricus would be seeking approval of Room Temp version of Vitaros in the USA..
DG, I do watch the ihub board. Silicon Investor is a good one too. I just do not like to join too many sites - too many user names and passwords to remember.